Giperfosfatemiya pri khronicheskoy bolezni pochek: sovremennaya strategiya korrektsii


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Рассматриваются механизмы нарушения минерального гомеостаза у пациентов с хронической болезнью почек (ХБП). Показано, что ранний и эффективный контроль минерально-костного метаболизма как на додиализной стадии, так и при лечении диализом - это ключ к успешному управлению ХБП.

Full Text

Restricted Access

References

  1. Moe S., Chertow G. Chronic kidney disease-mineral-bone disorder: a new paradigm // Am. J. Kidney Dis. - 2007; 14 (1): 3-12.
  2. Alon U. Fibroblast growth factor (FGF)23: a new hormone // Eur. J. Pediatr. -2011; 170: 545-54.
  3. Gattineni J., Bates C., Twombley K. et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1 // Am. J. Physiol. Renal. Physiol. - 2009; 297: F282-F291.
  4. Farrow E., Davis S., Summers L. et al. Initial FGF23-mediated signaling occurs in the distal convoluted tubule // J. Am. Soc. Nephrol. - 2009; 20: 955-60.
  5. Hasegawa H., Nagano N., Urakawa I. et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease // Kidney Int. - 2010; 78: 975-80.
  6. Bergwitz C., Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23 // Ann. Rev. Med. - 2010; 61: 91-104.
  7. Gutierrez O., Isakova T., Rhee E. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease // J. Am. Soc. Nephrol. - 2005; 16: 2205-15.
  8. Shimada T., Hasegawa H., Yamazaki Y. et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis // J. Bone Miner. Res. - 2004; 19: 429-35.
  9. Krajisnik T., Bjorklund P., Marsell R. et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells // J. Endocrinol. - 2007; 195: 125-31.
  10. Kawata T., Imanishi Y., Kobayashi K. et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism // J. Am. Soc. Nephrol. - 2007; 18: 2683-8.
  11. Vervloet M., Larsson T. Fibroblast growth factor-23 and Klotho in chronic kidney disease // Kidney International Supplements. - 2011; 1: 130-5.
  12. Tentori F., Blayney M., Albert J. et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS) // Am. J. Kidney Dis. - 2008; 52: 519-30.
  13. Wald R., Sarnak M., Tighiouart H. et al. Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study // Am. J. Kidney Dis. - 2008; 52: 531-40.
  14. Jean G., Terrat J., Vanel T. et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients // Nephrol. Dial. Transplant. - 2009; 24: 2792-6.
  15. Foley R., Collins A., Herzog C. et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults // J. Am. Soc. Nephrol. - 2009; 20: 397-404.
  16. Nasrallah M., El-Shehaby A., Salem M. et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients // Nephrol. Dial. Transplant. - 2010; 25: 2679-85.
  17. Block G., Hulbert-Shearon T., Levin N. et al. Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: a national study // Am J Kidney Dis. - 1998; 31: 607-17.
  18. Block G., Klassen P., Lazarus J. et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis // J. Am. Soc. Nephrol. - 2004; 15: 2208-18.
  19. Kestenbaum B., Sampson J., Rudser K. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease // J. Am. Soc. Nephrol. -2005; 16: 520-8.
  20. Levin A., Bakris G., Molitch M. et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease // Kidney Int. - 2007; 71: 31-8.
  21. Dhingra R., Sullivan L., Fox C. et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community // Arch. Intern. Med. - 2007; 167: 879-85.
  22. Tonelli M., Sacks F., Pfeffer M. et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease // Circulation. -2005; 112: 2627-33.
  23. Tonelli M., Curhan G., Pfeffer M. et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality // Circulation. - 2009; 120: 1784-92.
  24. Foley R., Collins A., Ishani A. et al. Calcium-phosphate levels and cardiovascular disease in communitydwelling adults: The Atherosclerosis Risk in Communities (ARIC) Study // Am. Heart. J. - 2008; 156: 556-63.
  25. de Boer I., Rue T., Kestenbaum B. Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III) // Am. J. Kidney Dis. - 2009; 53: 399-407.
  26. Gutierrez O., Mannstadt M., Isakova T. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis // N. Engl. J. Med. - 2008; 359: 584-92.
  27. Fliser D., Kollerits B., Neyer U. et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study // J. Am. Soc. Nephrol. - 2007; 18: 2600-8.
  28. Isakova T., Gutierrez O., Chang Y. et al. Phosphorus binders and survival on hemodialysis // J. Am. Soc. Nephrol. - 2009; 20: 388-96.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies